Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma
Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Drug: Adebrelimab and dalpiciclib Sponsors: Zhongzheng Xiang Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | HNSCC | Neoadjuvant Therapy | Research | Skin Cancer | Squamous Cell Carcinoma